FDA granted accelerated approval to Jaypirca (pirtobrutinib) for relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
